BNP Paribas Financial Markets Makes New $396,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

BNP Paribas Financial Markets purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 9,838 shares of the company's stock, valued at approximately $396,000.

Several other hedge funds have also bought and sold shares of KYMR. Blue Trust Inc. boosted its stake in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after acquiring an additional 270 shares during the period. KBC Group NV boosted its stake in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after acquiring an additional 752 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after acquiring an additional 2,350 shares during the period. Summit Investment Advisors Inc. boosted its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $251,000.

Analysts Set New Price Targets

A number of brokerages recently commented on KYMR. UBS Group dropped their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Citigroup began coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price target for the company. Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim reissued a "buy" rating and set a $52.00 price target on shares of Kymera Therapeutics in a research note on Monday, May 12th. Finally, Bank of America dropped their price target on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a research note on Monday, May 12th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.25.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,659 shares of company stock worth $324,567. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics Trading Up 2.3%

Shares of NASDAQ KYMR traded up $0.66 during midday trading on Wednesday, hitting $28.80. The company's stock had a trading volume of 1,371,151 shares, compared to its average volume of 565,720. The business's 50 day moving average is $28.78 and its two-hundred day moving average is $36.09. Kymera Therapeutics, Inc. has a 12-month low of $19.45 and a 12-month high of $53.27. The firm has a market cap of $1.88 billion, a P/E ratio of -12.31 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. During the same period in the prior year, the business posted ($0.69) earnings per share. The company's revenue for the quarter was up 114.6% on a year-over-year basis. On average, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.